logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10117907 B1

PDFFull Text
Date of Patent:
Nov. 06, 2018

Filed:

Feb. 16, 2016

Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases

Applicant:

The Arizona Board of Regents on Behalf of the University of Arizona, Tucson, AZ (US);

Inventors:

Robin Polt, Tucson, AZ (US);

Torsten A E Falk, Tucson, AZ (US);

Assignee:

Arizona Board of Regents on Behalf of the University of Arizona, a body corporate, Tucson, AZ (US);

Attorneys:

Don D. Cha

Hamilton DeSanctis & Cha, LLP

Primary Examiner:

Chang-Yu Wang

Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 49/00 (2006.01); C07K 14/00 (2006.01); A61K 38/18 (2006.01); C07K 14/475 (2006.01); C07K 14/48 (2006.01); C07K 14/575 (2006.01); A61K 38/17 (2006.01); A61K 38/22 (2006.01); C12N 5/0793 (2010.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 38/2278 (2013.01); C07K 2317/21 (2013.01); C07K 2317/41 (2013.01); C12N 5/0619 (2013.01); G01N 33/6896 (2013.01); G01N 2800/2814 (2013.01); G01N 2800/2821 (2013.01);
Abstract

A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PACreceptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PD, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PD, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.

Find Patent Forward Citations

Polt, Robin. (2018). Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases (U.S. Patent No. 10117907). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10117907

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…